Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SCN3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN3A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN3A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN2A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN2A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN1A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN1A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCARB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCARB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCARB1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCARB1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
S100A8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
S100A8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of S100A8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
RARRES2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
RARRES2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of RARRES2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTPRU Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRU Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRU sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTPRS Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRS Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRS sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTPRO Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTPRO Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of PTPRO sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →